ANAPTYSBIO INC. - COM
25.25
26-November-24 16:45:00
15 minutes delayed
Stocks
+1.15
+4.77%
Today's range
22.84 - 25.32
ISIN
N/A
Source
NASDAQ
-
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
07 Aug 2023 16:15:09 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Participation in Upcoming Investor Conferences
30 May 2023 16:15:00 By Nasdaq GlobeNewswire
-
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
11 May 2023 16:15:00 By Nasdaq GlobeNewswire
-
02 May 2023 09:15:00 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
06 Apr 2023 16:15:00 By Nasdaq GlobeNewswire
-
27 Mar 2023 18:50:32 By Nasdaq GlobeNewswire
-
01 Mar 2023 16:05:01 By Nasdaq GlobeNewswire
-
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
27 Feb 2023 16:05:01 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Stock Repurchase Plan
13 Jan 2023 09:00:00 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
05 Jan 2023 16:05:00 By Nasdaq GlobeNewswire
-
02 Dec 2022 09:00:00 By Nasdaq GlobeNewswire
-
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
21 Nov 2022 13:56:39 By Nasdaq GlobeNewswire
-
AnaptysBio to Participate in Upcoming November Investor Conferences
09 Nov 2022 14:10:17 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
08 Nov 2022 16:05:01 By Nasdaq GlobeNewswire
-
05 Oct 2022 09:00:00 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
12 Sep 2022 07:30:00 By Nasdaq GlobeNewswire
-
31 Aug 2022 16:15:00 By Nasdaq GlobeNewswire
-
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update
08 Aug 2022 16:05:03 By Nasdaq GlobeNewswire
-
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference
05 Aug 2022 16:00:00 By Nasdaq GlobeNewswire